Compare UCTT & ADMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UCTT | ADMA |
|---|---|---|
| Founded | 1991 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.4B |
| IPO Year | 2004 | 2012 |
| Metric | UCTT | ADMA |
|---|---|---|
| Price | $79.80 | $10.82 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $75.00 | $28.00 |
| AVG Volume (30 Days) | 911.6K | ★ 9.8M |
| Earning Date | 04-28-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.60 |
| Revenue | ★ $1,734,500,000.00 | $42,219,783.00 |
| Revenue This Year | $19.18 | $27.46 |
| Revenue Next Year | $17.36 | $22.11 |
| P/E Ratio | ★ N/A | $18.35 |
| Revenue Growth | N/A | ★ 43.85 |
| 52 Week Low | $18.02 | $7.21 |
| 52 Week High | $79.58 | $25.67 |
| Indicator | UCTT | ADMA |
|---|---|---|
| Relative Strength Index (RSI) | 72.93 | 44.50 |
| Support Level | $23.56 | $7.21 |
| Resistance Level | N/A | $16.48 |
| Average True Range (ATR) | 3.70 | 0.47 |
| MACD | 1.09 | 0.38 |
| Stochastic Oscillator | 96.88 | 87.29 |
Ultra Clean Holdings Inc, through its subsidiaries, manufactures and supplies production tools, modules, and subsystems for the semiconductor capital equipment industry. The product includes precision robotic solutions, gas delivery systems, and a variety of industrial and automation production equipment products; subsystems include wafer cleaning subsystems, chemical delivery modules, top-plate assemblies, frame assemblies, and process modules. Its customer base includes firms in the semiconductor capital equipment industry, medical, energy, industrial, flat panel, and research equipment industries. It has two segments: Products and Services. Its principal markets are the Americas, Asia Pacific, and EMEA.
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.